AGGF1: A Potential Drug Target and Biomarker (G55109)

Target Name: AGGF1

NCBI ID: G55109

AGGF1

AGGF1: A Potential Drug Target and Biomarker

Angiogenic factor with G-patch and FHA domains 1 (AGGF1) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. AGGF1 is characterized by the presence of G-patch and FHA domains, which give it unique structural features that are distinct from other proteins. These domains are involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion.

The G-patch domain is a type of transmembrane protein that is characterized by a long, N-terminal region that contains a conserved cysteine residue. This cysteine residue is involved in the formation of a disulfide bond, which is a common structural feature in proteins that involve protein-protein interactions. The G-patch domain is also known for its role in modulating the activity of various signaling pathways, including the TGF-β pathway.

The FHA domain is a unique protein-coding domain that is characterized by a long, N-terminal region that contains a conserved aspartate residue. This aspartate residue is involved in the formation of a hydrogen bond, which is a common structural feature in proteins that involve ionic bonds. The FHA domain is also known for its role in modulating the activity of various signaling pathways, including the PI3K/Akt signaling pathway.

The expression and function of AGGF1 are tightly regulated in various tissues of the body. AGGF1 is expressed in the brain, where it is involved in the regulation of neuronal communication and synaptic plasticity. In the heart, AGGF1 is expressed in the cardiac muscle, where it is involved in the regulation of contractility and cardiac remodeling. In the kidneys, AGGF1 is expressed in the glomeruli, where it is involved in the regulation of water and electrolyte balance. In the liver, AGGF1 is expressed in the hepatocytes, where it is involved in the regulation of metabolism and inflammation.

The potential drug targets of AGGF1 are numerous. For example, AGGF1 has been shown to be involved in the regulation of various signaling pathways, including the TGF-β, PI3K/Akt, and NF-kappa-B signaling pathways. It is also involved in the regulation of cellular adhesion, migration, and invasion, which are critical processes for the development and progression of various diseases, including cancer. In addition, AGGF1 is involved in the regulation of inflammation, which is a critical aspect of many diseases, including autoimmune diseases and chronic inflammatory disorders.

The G-patch and FHA domains of AGGF1 provide unique structural features that are involved in the regulation of various cellular processes. These domains are potential drug targets that could be exploited for the development of new therapies for a variety of diseases. For example, AGGF1 has been shown to be involved in the regulation of the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and inflammation. Therefore, compounds that can inhibit the activity of AGGF1 in this pathway could be potential drugs for the treatment of various diseases, including cancer.

In addition to its potential as a drug target, AGGF1 is also a potential biomarker for the diagnosis and prognosis of various diseases. The regulation of AGGF1 by various signaling pathways is disrupted in many diseases, including cancer, which provides a potential target for the development of biomarkers that can be used for the diagnosis and prognosis of these diseases. For example, AGGF1 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and proliferation. Therefore, compounds that can inhibit the activity of AGGF1 in this pathway could be potential biomarkers for

Protein Name: Angiogenic Factor With G-patch And FHA Domains 1

Functions: Promotes angiogenesis and the proliferation of endothelial cells. Able to bind to endothelial cells and promote cell proliferation, suggesting that it may act in an autocrine fashion

The "AGGF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGGF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets